Shan Wu, Ph.D.

Shan Wu joined Viridian as Chief Business Officer in 2023. She brings extensive experience in the biopharmaceutical industry with a strong track record in business development, corporate strategy, investor relations, communications, and operations. Prior to Viridian, Shan led business development and investor relations at Magenta Therapeutics, a company that she joined at launch and helped to build from a scientific platform to clinical-stage. Shan led multiple value-creating transactions at Magenta and supported all of the company’s private and public financings including its IPO. Earlier in her career, Shan led strategic forecasting at Biogen for the multiple sclerosis global commercial organization and prior to that was a management consultant at Clarion Healthcare (now Lumanity) where she led numerous strategy projects for biopharma clients, including for global launch, therapeutic area prioritization, and product differentiation.

Shan holds a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology and a B.S. in Computer and Electrical Engineering from the University of Virginia.